A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia

Schizophrenia Bulletin

Volumn 40, Issue 6, 2014, Pages 1433-1442

  Haig, George M ^a   Bain, Earle ^a   Robieson, Weining ^a   Othman, Ahmed A ^a,b   Baker, Jeffrey ^a   Lenz, Robert A ^a,c  

^a ABBVIE INC   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c AMGEN INC   (United States)

Author keywords

cognition disorders; cognitive dysfunction; histamine 3 receptor; humans; therapy

Indexed keywords

ABT 288; ARIPIPRAZOLE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; 2-(4'-(5-METHYLHEXAHYDROPYRROLO(3,4-B)PYRROL-1-YL)BIPHENYL-4-YL)-2H-PYRIDAZIN-3-ONE; HISTAMINE H3 RECEPTOR ANTAGONIST; PYRIDAZINE DERIVATIVE; PYRROLE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; AUTOMUTILATION; BARNES AKATHISIA SCALE; CALGARY DEPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SCHIZOPHRENIA; SLEEP DISORDER; SYMPTOM ASSESSMENT; TREATMENT DURATION; UNPLEASANT DREAM; XEROSTOMIA; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED; TREATMENT FAILURE;

ADULT; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; PYRROLES; SCHIZOPHRENIA; TREATMENT FAILURE;

EID: 84907145957     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt240     Document Type: Article

References (41)

1. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am. 2005;28:613-633.
2. Bartók E, Berecz R, Glaub T, Degrell I. Cognitive functions in prepsychotic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:621-625.
3. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24-32.
4. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51.
5. Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res. 1995;14:93-104.
6. Jin CY, Anichtchik O, Panula P. Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol. 2009;157:118-129.
7. Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008;154:1166-1181.
8. Altenbach RJ, Liu H, Banfor PN, et al. Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists. J Med Chem. 2007;50:5439-5448.
9. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther. 2011;336:38-46.
10. Fox GB, Esbenshade TA, Pan JB, et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile]: II. neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005;313:176-190.
11. Medhurst AD, Atkins AR, Beresford IJ, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321:1032-1045.
12. Egan M, Yaari R, Liu L, et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res. 2012;9:481-490.
13. GlaxoSmithKline. Study summary: A randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer's disease. http://www.gskclinicalstudyregister.com/result-comp-list.jsp?phase=All&st udyType=All&population=Adult&marketing=All&compou nd=GSK239512. Accessed August 13, 2012.
14. Herring WJ, Wilens TE, Adler LA, et al. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012;73:e891-e898.
15. Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann- Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012;26:421-434.
16. Egan M, Zhao X, Gottwald R, et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res. 2013;146:224-230.
17. GlaxoSmithKline. Study summary: a randomized doubleblind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia. http://www.gsk-clinicalstudyregister.com/result-comp-list.jsp?phase=All&studyType=All&pop ulation=Adult&marketing=All&compound=GSK239512. Accessed August 23, 2012.
18. Esbenshade TA, Browman KE, Miller TR, et al. Pharmacological properties and procognitive effects of ABT- 288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2012;343:233-245.
19. Othman AA, Haig G, Florian H, et al. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers [published online ahead of print 2013]. Br J Clin Pharmacol. doi: 10.1111/bcp.12281.
20. Othman AA, Haig G, Florian H, Locke C, Zhang J, Dutta S. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers. Br J Clin Pharmacol. 2013;75:1299-1311.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini- International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33; quiz 34-57.
23. Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;261:76.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Vol Publication ADM 76-338. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976.
25. Barnes T. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
26. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201-208.
27. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165:214-220.
28. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
29. Patterson T, Goldman S. The UCSD performance-based skills assessment (UPSA-2). Copy written material R-10-06. 2005.
30. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25:159-163.
31. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
32. MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities (MedDRA). Version 14.0. Chantilly, VA: MedDRA Maintenance and Support Services Organization.
33. Umbricht D, Murray S, Lowe D, et al. The Effect of the Partial Nicotinic Alpha7 Receptor Agonist R3487 on Cognitive Deficits in Schizophrenia. Hollywood, FL: ACNP; 2009.
34. Dunbar G, Hosford D, Lieberman J, Segreti A. The alpha7 nicotinic receptor agonist TC-5619 had beneficial effects with favorable tolerability in a phase 2 trial in cognitive dysfunction in schizophrenia. In: 13th International Congress on Schizophrenia Research; April 2-6; Colorado Springs, Colorado.
35. Anruhlf I. Results of clinical trials of tripolisant in narcolepsy and Parkinson's disease. Eur Neuropsychopharm. 2009;19:S204.
36. Iannone R, Palcza J, Renger JJ, et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther. 2010;88:831-839.
37. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163:713-721.
38. National Center for Advancing Translational Sciences, National Institutes of Health. Pfizer Inc., PF-03654746. http://www.ncats.nih.gov/files/PF-03654746.pdf. Accessed September 04, 2012.
39. Boyer S, Palumbo D, Chappell P, Li B, Pinter G. Results of an H3 receptor antagonist clinical trial in adults diagnosed with ADHD. In: International Society for CNS Clinical Trials and Methodology; February 22-24; Washington DC.
40. Haig G, Meier A, Pritchett Y, et al. Evaluation of efficacy and safety of the H3 antagonist ABT-288 in mild-to-moderate Alzheimer's disease. In: Alzheimer's Association International Conference; July 14-19; British Columbia, Canada.
41. Nuutinen S, Panula P. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol. 2011;709:95-107.